A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine

被引：2
作者：
Ripamonti, Diego [1 ,5 ]
Rusconi, Stefano [2 ,3 ]
Zazzi, Maurizio [4 ]
机构：
[1] ASST Papa Giovanni XXIII, Infect Dis Unit, Bergamo, Italy
[2] Univ Milan, Legnano Gen Hosp, ASST Ovest Milanese, Infect Dis Unit, Milan, Italy
[3] Univ Milan, DIBIC Luigi Sacco, Milan, Italy
[4] Univ Siena, Dept Med Biotechnol, Siena, Italy
[5] ASST Papa Giovanni XXIII, Bergamo, Italy
来源：
AIDS | 2024年 / 38卷 / 02期
关键词：
HIV;
D O I：
10.1097/QAD.0000000000003760
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：263 / 265
页数：3
相关论文
共 23 条
[1]   Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies [J].
Ait-Khaled, Mounir ;
Madero, Juan Sierra ;
Estrada, Vicente ;
Gulminetti, Roberto ;
Hagins, Debbie ;
Tsai, Hung-Chin ;
Man, Choy ;
Sievers, Jorg ;
Grove, Richard ;
Zolopa, Andrew ;
Wynne, Brian ;
van Wyk, Jean .
HIV RESEARCH & CLINICAL PRACTICE, 2021, 23 (01) :9-14
[2]   Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries [J].
Akinwunmi, Babatunde ;
Buchenberger, Daniel ;
Scherzer, Jenny ;
Bode, Martina ;
Rizzini, Paolo ;
Vecchio, Fabio ;
Roustand, Laetitia ;
Nachbaur, Gaelle ;
Finkielsztejn, Laurent ;
Chounta, Vasiliki ;
Van de Velde, Nicolas .
SEXUALLY TRANSMITTED INFECTIONS, 2021, 97 (08) :566-573
[3]  
Andrea A., 2022, AIDS, V36, P39
[4]   Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) [J].
Chounta, Vasiliki ;
Overton, Edgar T. ;
Mills, Anthony ;
Swindells, Susan ;
Benn, Paul D. ;
Vanveggel, Simon ;
van Solingen-Ristea, Rodica ;
Wang, Yuanyuan ;
Hudson, Krischan J. ;
Shaefer, Mark S. ;
Margolis, David A. ;
Smith, Kimberly Y. ;
Spreen, William R. .
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (06) :849-862
[5]   Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials [J].
Fournier, Anna L. ;
Hocqueloux, Laurent ;
Braun, Dominique L. ;
Metzner, Karin J. ;
Kouyos, Roger D. ;
Raffi, Francois ;
Briant, Anais R. ;
Martinez, Esteban ;
De Lazzari, Elisa ;
Negredo, Eugenia ;
Rijnders, Bart ;
Rokx, Casper ;
Guenthard, Huldrych F. ;
Parienti, Jean-Jacques .
OPEN FORUM INFECTIOUS DISEASES, 2022, 9 (06)
[6]  
Gandhi M, 2023, CROI 2023
[7]   Single-center experience evaluating and initiating people with HIV on long-acting cabotegravir/rilpivirine [J].
Hill, Lucas A. ;
Abulhosn, Kari K. ;
Yin, Jeffrey F. ;
Bamford, Laura P. .
AIDS, 2023, 37 (04) :605-609
[8]   High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda [J].
Kennedy, Caitlin E. E. ;
Zhao, Tongying ;
Vo, Anh Van ;
Nakubulwa, Rosette ;
Nabakka, Proscovia ;
Jackson, Jade ;
Rosen, Joseph G. G. ;
Chang, Larry W. W. ;
Reynolds, Steven J. J. ;
Quinn, Thomas C. C. ;
Nakigozi, Gertrude ;
Kigozi, Godfrey ;
Kagaayi, Joseph ;
Nalugoda, Fred ;
Ddaaki, William G. G. ;
Grabowski, M. Kate ;
Nakyanjo, Neema .
AIDS PATIENT CARE AND STDS, 2023, 37 (06) :316-322
[9]   Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3-or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial [J].
Llibre, Josep M. ;
Brites, Carlos ;
Cheng, Chien-Yu ;
Osiyemi, Olayemi ;
Galera, Carlos ;
Hocqueloux, Laurent ;
Maggiolo, Franco ;
Degen, Olaf ;
Taylor, Stephen ;
Blair, Elizabeth ;
Man, Choy ;
Wynne, Brian ;
Oyee, James ;
Underwood, Mark ;
Curtis, Lloyd ;
Bontempo, Gilda ;
van Wyk, Jean .
CLINICAL INFECTIOUS DISEASES, 2023, 76 (04) :720-729
[10]   Real World Data on Forgiveness to Uncomplete Adherence to Bictegravir/Emtricitabine/Tenofovir Alafenamide [J].
Maggiolo, Franco ;
Valenti, Daniela ;
Teocchi, Rodolfo ;
Comi, Laura ;
Di Filippo, Elisa ;
Rizzi, Marco .
JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2022, 21
123